J. Carles

发表

Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment

J. Carles, I. Chirivella, M. Climent, 2012, Cancer and Metastasis Reviews.

RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas

César Serrano, Joan Carles, J. Carles, 2016, Cancer.

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.

R. Tothill, D. Bowtell, C. Plass, 2016, The Lancet. Oncology.

Molecular basis for the treatment of renal cell carcinoma

J. Carles, C. Valverde, J. Rodon, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents

J. Carles, J. Bellmunt, C. Montagut, 2007, BJU international.

Acute aortic dissection during sorafenib-containing therapy.

J. Carles, C. Serrano, C. Suarez, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Her-2/neu Expression in Prostate Cancer

J. Lloreta, M. Salido, J. Carles, 2004, Clinical Cancer Research.

Relationship between radiation-induced apoptosis of T lymphocytes and chronic toxicity in patients with prostate cancer treated by radiation therapy: a prospective study.

J. Carles, B. Bellosillo, N. Rodríguez, 2014, International journal of radiation oncology, biology, physics.

Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria

J. Carles, E. Felip, J. Tabernero, 2019, Clinical Cancer Research.

Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

J. Carles, E. Esteban, J. Contreras, 2013, British Journal of Cancer.

Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer

G. Castellano, J. Carles, B. Mellado, 2020, Frontiers in Oncology.

BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours

J. Carles, S. Ramón y. Cajal, C. Serrano, 2013, Histopathology.

Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.

J. Carles, C. Lord, T. Casals, 2020, European urology.

Towards a New Classification for Metastatic Prostate Cancer.

J. Carles, J. Mateo, 2019, European urology.

Metastatic nonclear renal cell carcinoma current review in evolving treatment strategies

J. Carles, J. Mateo, C. Suarez, 2021, Current opinion in urology.

Enzalutamide in metastatic prostate cancer before chemotherapy.

F. Saad, J. Carles, H. Scher, 2014, The New England journal of medicine.

Detection of circulating tumor DNA for advanced bladder cancer: where are we going?

J. Carles, C. Suarez, M. González, 2018, Translational andrology and urology.

Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer.

J. Baselga, J. Carles, J. Albanell, 2000, European journal of cancer.

Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223

J. Carles, M. Climent, A. Rodriguez-Vida, 2018, Clinical and Translational Oncology.

Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor

J. Fletcher, J. Carles, P. Nuciforo, 2020, Molecular Cancer Therapeutics.

Metabolic syndrome increases the risk of aggressive prostate cancer detection

J. Carles, J. Morote, J. Reventós, 2013, BJU international.

Risk Factors for Overall Survival Outcome in Surgically Treated Human Papillomavirus-Negative and Positive Patients with Oropharyngeal Cancer.

F. Saad, J. Carles, M. Wirth, 2017 .

Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy?

J. Carles, C. Valverde, J. Morote, 2013, Clinical and Translational Oncology.

Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function.

J. Carles, J. Bellmunt, C. Serrano, 2012, European journal of cancer.

A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01

J. Carles, V. Guillem, J. Bellmunt, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.

J. Carles, M. Climent, J. Albanell, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Recommendations for the optimal management of early and advanced urothelial carcinoma.

J. Carles, M. Climent, J. Maroto, 2012, Cancer treatment reviews.

Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial

G. Scagliotti, J. Carles, G. del Conte, 2021, Cancer Immunology, Immunotherapy.

Emerging therapies for urothelial cancer.

J. Carles, C. Serrano, C. Valverde, 2012, Cancer treatment reviews.

SEOM clinical guidelines for the treatment of invasive bladder cancer

J. Carles, A. Font, R. Morales, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Feasibilty study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function

J. Carles, J. Albanell, I. Tusquets, 2006 .

Gemcitabine/carboplatin in advanced urothelial cancer.

J. Carles, M. Nogué, 2001, Seminars in oncology.

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.

F. Saad, J. Carles, M. Wirth, 2016, The Lancet. Oncology.

An observational, multicentre study of cabazitaxel in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel (CAPRISTANA)

J. Carles, S. Hitier, A. Tomova, 2018, BJU international.

Cyclophosphamide and ifosfamide combination as neoadjuvant chemotherapy for locally advanced nonsmall‐cell lung cancer: A meta‐analytic review

J. Carles, R. Rosell, N. Ribelles, 1990, Journal of surgical oncology.

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

J. Carles, B. Tombal, F. Calabrò, 2022, The Lancet.

Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER

J. Carles, H. Scher, A. Armstrong, 2022, European journal of cancer.

Circulating Tumor Cells as a Biomarker of Survival and Response to Radium‐223 Therapy: Experience in a Cohort of Patients With Metastatic Castration‐Resistant Prostate Cancer

J. Carles, B. Mellado, J. Pérez-Gracia, 2018, Clinical genitourinary cancer.

Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration‐resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial

J. Carles, T. Dorff, C. Higano, 2017, Clinical genitourinary cancer.

SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)

J. Carles, M. Climent, B. Mellado, 2017, Clinical and Translational Oncology.

Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.

J. Carles, M. Climent, B. Mellado, 2012, Critical reviews in oncology/hematology.

Non-metastatic castration-resistant prostate cancer (CPRCM0), an old scenario with renewed clinical interest.

J. Carles, X. Maldonado, J. Planas, 2014, Actas urologicas espanolas.

Non-metastatic castration-resistant prostate cancer (CPRCM0), an old scenario with renewed clinical interest

J. Carles, J. Morote, X. Maldonado, 2014 .

Recommendations on the management of controversies in advanced castrate-resistant prostate cancer

J. Carles, M. Climent, J. Maroto, 2012 .

Castration-resistant metastatic prostate cancer: current status and treatment possibilities

J. Carles, M. Climent, D. Castellano, 2012, Clinical and Translational Oncology.

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

J. Carles, E. Gallardo, B. Mellado, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer

J. Carles, I. Durán, J. Jiao, 2020, Clinical Pharmacokinetics.

Predictive modelling in hormone-refractory prostate cancer (HRPC)

J. Carles, J. Albanell, J. Bellmunt, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Effects of rilpivirine on human adipocyte differentiation , gene 2 expression and release of adipokines and cytokines 3 4 5 6 7

J. Carles, Julieta Díaz-Delfína, Pere Domingob, 2012 .

Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): results of phase III PREVAIL study.

J. Carles, J. Bono, K. Miller, 2014, Clinical advances in hematology & oncology : H&O.

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

J. Carles, B. Tombal, C. Sternberg, 2019, The New England journal of medicine.

Expression of cyclooxygenase-2 mRNA in peripheral blood of head and neck cancer patients and in healthy controls. A pilot study

J. Carles, P. Gascón, M. Monzó, 2007, Acta oto-laryngologica.

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

P. Kantoff, F. Saad, C. Parker, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Castration-resistant prostate cancer: where are we going?].

J. Carles, M. Climent, D. Castellano, 2012, Actas urologicas espanolas.

Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies

J. Carles, E. Sokol, E. Antonarakis, 2022, JCO precision oncology.

Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.

A. Ravaud, T. Powles, J. Carles, 2019, European urology.

The influence of treatment sequence in the prognostic value of TMPRSS2‐ERG as biomarker of taxane resistance in castration‐resistant prostate cancer

J. Carles, B. Mellado, A. Prat, 2019, International journal of cancer.

Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group.

J. Carles, B. Tombal, G. Kramer, 2020, European urology oncology.

A phase IIb trial of docetaxel concurrent with radiotherapy plus hormotherapy versus radio hormonotherapy in high-risk localized prostate cancer (QRT SOGUG trial): Preliminary report for design, tolerance, and toxicity.

J. Carles, B. Mellado, J. Bellmunt, 2015 .

Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract

J. Carles, B. Mellado, A. Font, 2003, Cancer.

Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine

J. Baselga, J. J. de la Cruz, J. Carles, 2002, Cancer.

Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer

J. Carles, L. Paz-Ares, X. G. Del Muro, 2002, British Journal of Cancer.

Phase II/III trial of induction chemotherapy (ICT) with cisplatin/5-fluorouracil (PF) vs. docetaxel (T) plus PF (TPF) followed by chemoradiotherapy (CRT) vs. CRT for unresectable locally advanced head and neck cancer (LAHNC)

J. Carles, R. Hitt, H. Cortés-Funes, 2005 .

215 Gemcitabine, ifosfamide and cisplatin (GIP) in the treatment of advanced non-small cell lung cancer. A phase II trial

J. Carles, I. Tusquets, R. Ibeas, 1997 .

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

J. Baselga, J. J. de la Cruz, J. Carles, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hyperprogressive disease in patients with metastatic genitourinary tumors treated with immune checkpoint inhibitors.

J. Carles, C. Serrano, C. Valverde, 2019, Journal of Clinical Oncology.

Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.

J. Carles, J. Tabernero, Á. Arcusa, 1998, Acta oncologica.

Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.

J. Carles, M. Climent, E. Esteban, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).

J. Carles, M. Margelí, J. Aparicio, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Bilateral testicular germ cell tumours: a single hospital experience

J. Carles, C. Valverde, C. Suarez, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

E400P in advanced seminoma of good prognosis according to the international germ cell cancer collaborative group (IGCCCG) classification: the Spanish Germ Cell Cancer Group experience.

J. Carles, R. Salazar, J. Aparicio, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.

A. Tafreshi, J. Carles, S. Oudard, 2022, European urology.

Second‐line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second‐line Studies

J. Carles, S. Srinivas, D. Vis, 2017, Clinical genitourinary cancer.

Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.

J. Carles, S. Srinivas, S. Salah, 2016, Clinical genitourinary cancer.

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.

T. H. Klotz, S. Culine, J. Hainsworth, 2022, The Lancet. Oncology.

Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study.

J. Carles, A. Llombart‐Bosch, R. Andrés, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

BRAF and KRAS mutations in penile cancer and their correlation with clinical features.

J. Carles, C. Serrano, J. Hernández-Losa, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study

J. Carles, I. Chirivella, M. Climent, 2013, British Journal of Cancer.

The influence of metabolic syndrome on prostate cancer risk detection and its aggressiveness.

J. Carles, C. Valverde, J. Morote, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial.

J. Carles, E. Gallardo, B. Mellado, 2022, European journal of cancer.

Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302

J. Carles, H. Scher, A. Armstrong, 2022, European journal of cancer.

A Phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer.

J. Carles, N. Agarwal, B. McGregor, 2022, Future oncology.

Is dose-dependent response to bacillus Calmette-Guérin treatment in urothelial carcinoma?

J. Carles, R. Morales-Barrera, F. Racca, 2017 .

Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.

J. Carles, B. Tombal, C. Sternberg, 2020, The Lancet. Oncology.

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

F. Saad, J. Carles, M. Wirth, 2019, BMC Cancer.

Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study

J. Carles, D. George, S. Slovin, 2017, JAMA oncology.

Radium-223 international early access program: results from the Spanish subset.

J. Carles, B. Mellado, E. Esteban, 2018, Future oncology.

Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone‐Releasing Hormone Agonist Therapy

J. Carles, J. Morote, X. Maldonado, 2017, Clinical genitourinary cancer.

Free Testosterone During Androgen Deprivation Therapy Predicts Castration‐Resistant Progression Better Than Total Testosterone

J. Carles, J. Morote, X. Maldonado, 2017, The Prostate.

TALAPRO-2: a placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC).

J. Carles, N. Agarwal, A. Fay, 2020, Journal of Clinical Oncology.

Results of a phase II study of pralatrexate in patients with advanced/metastatic relapsed transitional cell carcinoma of the urinary bladder.

J. Carles, N. Agarwal, Y. Loriot, 2012 .

Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease

J. Carles, J. Mateo, C. Suarez, 2022, Frontiers in Oncology.

Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment

J. Carles, I. Chirivella, M. Climent, 2012, Cancer and Metastasis Reviews.

Excision repair cross-complementing 1 (ERCC1) and survival in advanced bladder cancer: Confirmatory results using immunohistochemistry.

J. Lloreta, J. J. de la Cruz, J. Carles, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line treatment with sunitinib monotherapy in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy: Pretreatment levels of IL8 and Hounsfield units as predictors of clinical benefit.

J. Carles, E. Gallardo, J. Maroto, 2010 .

Central venous brachial catheter (P.A.S. port TM) and catheter scanning system (cath‐finder TM)

J. Carles, R. Rosell, A. Alastrué, 1994, Journal of surgical oncology.

Abiraterone in metastatic prostate cancer without previous chemotherapy.

F. Saad, E. Basch, J. Carles, 2013, The New England journal of medicine.

Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer

J. Carles, R. Rosell, A. Abad, 1992, Investigational New Drugs.

Therapeutic challenge for Isospora belli enteritis in an AIDS patient who developed Lyell syndrome after co-trimoxazole therapy.

J. Carles, B. Clotet, C. Tural, 1989, The American journal of gastroenterology.

A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.

C. Rubio-Perez, J. Carles, E. Felip, 2021, Radiology.

Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study.

J. Carles, B. Mellado, L. Paz-Ares, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

J. Baselga, J. J. de la Cruz, J. Carles, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid

N. López-Bigas, C. Rubio-Perez, J. Carles, 2018, Clinical Cancer Research.

Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope.

J. Carles, C. Valverde, J. Morote, 2016, Cancer treatment reviews.

Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors

J. Fletcher, J. Carles, S. George, 2020, BMC Cancer.

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

Salvatore Piscuoglio, Xavier de la Cruz, Jordi Rodon, 2015, Nature Communications.

Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer

J. Carles, J. Mateo, C. Suarez, 2019, Current Oncology Reports.

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 Phase III study design.

J. Carles, N. Agarwal, A. Fay, 2022, Future oncology.

PARP inhibitors in advanced prostate cancer: when to use them?

J. Carles, J. Mateo, C. Suarez, 2021 .

Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer.

J. Carles, J. Albanell, A. Navarro, 2006, International journal of radiation oncology, biology, physics.

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

A. Ravaud, T. Powles, J. Carles, 2021, Nature Medicine.

Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma

J. Carles, M. Climent, E. Gallardo, 2014, PloS one.

Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry

J. Carles, S. Hitier, G. Di Lorenzo, 2020, Cancers.

Kidney cancer PDOXs reveal patient‐specific pro‐malignant effects of antiangiogenics and its molecular traits

J. Carles, S. Aguilar, A. Amadori, 2020, EMBO molecular medicine.

Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients

J. Carles, F. Viñals, S. Indraccolo, 2016, Cell reports.

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

F. Saad, J. Carles, K. Miller, 2015, The Lancet. Oncology.

Hormonal changes after localized prostate cancer treatment. Comparison between external beam radiation therapy and radical prostatectomy.

J. Carles, J. Morote, D. Lorente, 2016, Actas urologicas espanolas.

PROSTRATEGY: A Spanish Genitourinary Oncology Group (SOGUG) multi-arm multistage (MAMS) phase III trial of immunotherapy strategies in high-volume metastatic hormone-sensitive prostate cancer

J. Carles, F. Zambrana, M. Quintela, 2019, Annals of Oncology.

Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors

J. Fletcher, J. Carles, S. George, 2020, BMC Cancer.

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

S. Culine, J. Carles, J. Bellmunt, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Unveiling changes in the landscape of patient populations in cancer early drug development

J. Carles, P. Gómez, C. Hierro, 2016, Oncotarget.

An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies

A. Ravaud, T. Powles, J. Carles, 2019, Annals of Oncology.

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

F. Saad, J. Carles, M. Wirth, 2019, BMC Cancer.

Efficacy and Safety of Abiraterone Acetate in Elderly ( ≥ 75 Years ) Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer

J. Carles, D. Rathkopf, P. Mulders, 2015 .

The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.

J. Carles, K. Miller, J. Gschwend, 2017, European urology.

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.

J. Carles, Choung-Soo Kim, A. Font, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.

J. Carles, B. Tombal, C. Sternberg, 2021, European urology.

Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study.

J. Carles, J. Bono, B. Tombal, 2020 .

Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials

J. Carles, E. Felip, P. Nuciforo, 2020, JCO precision oncology.

A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer.

J. Carles, B. Mellado, J. Bono, 2018 .

767PRESPONSE RATES AND OUTCOMES WITH ENZALUTAMIDE FOR PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER AND VISCERAL DISEASE IN THE PREVAIL TRIAL.

J. Carles, C. Higano, B. Tombal, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

F. Saad, J. Hainsworth, J. Carles, 2014, European urology.

Randomized trial for the control of acute vomiting in cisplatin-treated patients: high-dose metoclopramide with dexamethasone and lorazepam as adjuncts versus high-dose alizapride plus dexamethasone and lorazepam. Study of the incidence of delayed emesis.

J. Carles, R. Rosell, N. Ribelles, 1991, Oncology.

A phase II study of days 1 and 8 cisplatin and recombinant alpha‐2B interferon in advanced non‐small cell lung cancer

J. Carles, A. Ariza, R. Rosell, 1991, Cancer.

A randomized study of two vindesine plus cisplatin‐containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non‐small cell lung cancer

J. Carles, R. Rosell, N. Ribelles, 1990, Cancer.

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors

J. Carles, S. George, C. Serrano, 2017, Targeted Oncology.

Comparing Cisplatin Plus Fluorouracil to Paclitaxel , Cisplatin , and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer

J. Carles, L. Paz-Ares, R. Hitt, 2006 .

Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.

J. Carles, L. Paz-Ares, R. Hitt, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma.

J. Carles, L. Paz-Ares, J. Aparicio, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor.

J. Carles, C. Valverde, J. Morote, 2020, Cancer treatment reviews.

LINE-1 methylation in leukocyte DNA, interaction with phosphatidylethanolamine N-methyltransferase variants and bladder cancer risk

S. Serrano, N. Malats, M. Kogevinas, 2014, British Journal of Cancer.

Prognostic Index Model for Progression‐Free Survival in Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone

P. Kantoff, F. Saad, J. Carles, 2017, Clinical genitourinary cancer.

Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients.

J. Carles, E. Gallardo, B. Mellado, 2019, International journal of radiation oncology, biology, physics.

Carboplatin-Gemcitabine Treatment of Patients with Transitional Cell Carcinoma of the Bladder and Impaired Renal Function

J. Carles, M. Doménech, R. Ibeas, 2000, Oncology.

Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).

Joaquim Bellmunt, Joan Carles, Jordi Rubió, 2010, The Lancet. Oncology.

Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients.

J. Carles, R. Rosell, A. Abad, 1992, European journal of cancer.

Role of Immunotherapy in Castration‐Resistant Prostate Cancer (CRPC)

J. Carles, C. Valverde, J. Morote, 2014, BJU international.

Massive tumor implantation in the endoscopic resected area in modified nephroureterectomy.

J. Carles, A. Gelabert-Más, Ó. Bielsa, 1997, The Journal of urology.

Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial.

J. Carles, R. López-López, R. Mesía, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of acromegaly and two malignancies: colorectal cancer and non-Hodgkin's lymphoma.

J. Carles, A. Goday, K. Villadiego, 1994, Annals of Oncology.

775 The phase 3 COU-AA-302 study of abiraterone acetate (AA) in men with chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC): Stratified analysis based on pain, prostate-specific antigen (PSA) and Gleason score (GS)

J. Carles, J. Gschwend, H. Poppel, 2016 .

Phase II clinical trial of PM00104 (Zalypsis®) in urothelial carcinoma patients progressing after first-line platinum-based regimen

J. Carles, J. Maroto, J. Bellmunt, 2014, Cancer Chemotherapy and Pharmacology.

E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor

M. Gut, J. Barretina, J. Fletcher, 2021, Oncogene.

Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.

J. Carles, J. Arribas, S. Landolfi, 2018, The oncologist.

Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer.

J. Carles, A. Ariza, R. Rosell, 1993, Lung cancer.

Artificial intelligence combining radiomics and clinical data for predicting response to immunotherapy

J. Carles, E. Felip, J. Tabernero, 2019, Annals of Oncology.

Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program.

F. Saad, J. Carles, M. Wirth, 2019, Clinical genitourinary cancer.

Prognostic index model (PIM) for overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy treated with abiraterone acetate (AA).

P. Kantoff, F. Saad, J. Carles, 2015 .

Radium-223 (Ra-223) therapy after abiraterone (Abi): Analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

F. Saad, J. Carles, M. Wirth, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

2561 Effects of concomitant use of abiraterone and/or enzalutamide with radium-223 on safety and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (EAP)

F. Saad, J. Carles, M. Wirth, 2015 .

Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP).

F. Saad, J. Carles, M. Wirth, 2016 .

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study

J. Carles, E. Gallardo, A. González del Alba, 2007, British Journal of Cancer.

Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

J. Carles, H. Scher, J. Bono, 2012 .

Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

J. Carles, H. Scher, E. Small, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.

A. Tafreshi, J. Carles, J. Bono, 2019, Journal of Clinical Oncology.

Talapro-2: A 2-part, placebo-controlled phase 3 study of talazoparib (TALA) with background enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair deficiencies.

J. Carles, N. Agarwal, A. Fay, 2018 .

Sequential Combination of Methotrexate (MTX), 5‐Fluorouracil (FU), and High‐Dose Folinic Acid (FA) in Advanced Colorectal Cancer: Double Biochemical Modulation?

J. Carles, R. Rosell, A. Abad, 1991, American journal of clinical oncology.

Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution

J. Carles, J. Hernández-Losa, S. Simonetti, 2023, bioRxiv.

Randomised phase III trial of vinflunine (V) plus best supportive care (B) vs B alone as 2nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium (TCCU)

J. Carles, C. Théodore, L. Sengeløv, 2008 .

73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis

J. Carles, J. Bono, S. Oudard, 2021, Annals of Oncology.

Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer.

J. Carles, E. Gallardo, J. Gayo, 2010, International Journal of Radiation Oncology, Biology, Physics.

Eccrine porocarcinoma presenting with scrotal lymphedema: a case report and review of systemic treatment.

J. Carles, C. Valverde, R. Morales, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.

J. Carles, J. García-Saenz, R. Mesía, 2016, International journal of radiation oncology, biology, physics.

Phase III non-inferiority study of cabazitaxel (C) 20 mg/m2 (C20) versus 25 mg/m2 (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).

J. Carles, J. Bono, Choung-Soo Kim, 2016 .

A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse.

J. Carles, A. Laplanche, K. Fizazi, 2014 .

Efficacy of las 30451 in the prevention of cisplatin induced emesis

J. Carles, L. Cirera, C. Vadell, 1993 .

5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors.

J. Carles, R. Rosell, A. Abad, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis.

J. Carles, Jorge Ortiz, S. Srinivasan, 2023, Future oncology.

Predicting response to abiraterone acetate (AA): mRNA biomarker analysis of study COU-AA-302.

J. Carles, H. Scher, J. Bono, 2014 .

A proposed new model for prognostic stratification of poor-risk patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy.

S. Iacobelli, J. Carles, V. Adamo, 2014 .

Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen

J. Carles, H. Pandha, J. Bono, 2012 .

Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment.

J. Carles, J. Mateo, C. Suarez, 2023, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Enzalutamide (ENZA) in men with chemotherapy-Naïve metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study.

F. Saad, J. Carles, J. Bono, 2015 .

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

J. Carles, N. Agarwal, C. Szczylik, 2023, The Lancet.

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

J. Carles, N. Agarwal, C. Szczylik, 2023, Journal of Clinical Oncology.

PROSELICA: Health-related quality of life (HRQL) and post-hoc analyses for the phase 3 study assessing cabazitaxel 20 (C20) vs 25 (C25) mg/m2 post-docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

J. Carles, J. Bono, Choung-Soo Kim, 2016 .

Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel–Lindau-Disease-Associated Tumors

J. Carles, C. Suarez, M. Vieito, 2023, Medical Sciences.

First-line phase II trial of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma unsuitable for cytokine treatment

J. Carles, V. Guillem, J. Bellmunt, 2007 .

Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).

F. Saad, J. Carles, J. Bono, 2014 .

Calcification of lymph node metastases from prostate carcinoma after hormonal treatment: A case report

J. Carles, R. Ibeas, M. Busto, 1997, The Prostate.

Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function.

J. Carles, J. Albanell, I. Tusquets, 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities.

J. Carles, C. Valverde, R. Morales, 2009, European journal of cancer.

Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

D. Amadori, S. Fosså, A. Haese*, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)

J. Carles, M. Climent, B. Mellado, 2017, Clinical and Translational Oncology.

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

F. Saad, J. Carles, H. Scher, 2014 .

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

D. Amadori, S. Fosså, C. Parker, 2011 .

Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients.

J. Lloreta, X. Castells, J. Carles, 2009, European journal of cancer.